NAV

6-[N-(4-(Aminomethyl)Phenyl)Carbamyl]-2-Naphthalenecarboxamidine

Identification

Generic Name
6-[N-(4-(Aminomethyl)Phenyl)Carbamyl]-2-Naphthalenecarboxamidine
DrugBank Accession Number
DB02398
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 318.3724
Monoisotopic: 318.148061218
Chemical Formula
C19H18N4O
Synonyms
Not Available
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UUrokinase-type plasminogen activatorNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as naphthalene-2-carboxanilides. These are naphthalene-2-carboxamides, where the carboxamide group is substituted with an aniline.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Naphthalenes
Sub Class
Naphthalenecarboxylic acids and derivatives
Direct Parent
Naphthalene-2-carboxanilides
Alternative Parents
Aromatic anilides / Phenylmethylamines / Benzylamines / Aralkylamines / Secondary carboxylic acid amides / Amino acids and derivatives / Carboximidamides / Carboxamidines / Organopnictogen compounds / Organooxygen compounds
show 3 more
Substituents
Amidine / Amine / Amino acid or derivatives / Aralkylamine / Aromatic anilide / Aromatic homopolycyclic compound / Benzylamine / Carboxamide group / Carboximidamide / Carboxylic acid amidine
show 14 more
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available
InChI Key
NLBDETRVUYOIHQ-UHFFFAOYSA-N
InChI
InChI=1S/C19H18N4O/c20-11-12-1-7-17(8-2-12)23-19(24)16-6-4-13-9-15(18(21)22)5-3-14(13)10-16/h1-10H,11,20H2,(H3,21,22)(H,23,24)
IUPAC Name
N-[4-(aminomethyl)phenyl]-6-carbamimidoylnaphthalene-2-carboxamide
SMILES
NCC1=CC=C(NC(=O)C2=CC=C3C=C(C=CC3=C2)C(N)=N)C=C1

References

General References
Not Available
PubChem Compound
447733
PubChem Substance
46508312
ChemSpider
394746
BindingDB
50138662
ChEMBL
CHEMBL324168
ZINC
ZINC000002047485
PDBe Ligand
239
PDB Entries
1owh / 4fuc

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0135 mg/mLALOGPS
logP1.67ALOGPS
logP2.1Chemaxon
logS-4.4ALOGPS
pKa (Strongest Acidic)15.5Chemaxon
pKa (Strongest Basic)11.29Chemaxon
Physiological Charge2Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count4Chemaxon
Polar Surface Area104.99 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity108.19 m3·mol-1Chemaxon
Polarizability36.1 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9716
Blood Brain Barrier+0.9919
Caco-2 permeable-0.582
P-glycoprotein substrateNon-substrate0.6189
P-glycoprotein inhibitor INon-inhibitor0.9131
P-glycoprotein inhibitor IIInhibitor0.539
Renal organic cation transporterNon-inhibitor0.6831
CYP450 2C9 substrateNon-substrate0.7505
CYP450 2D6 substrateNon-substrate0.7327
CYP450 3A4 substrateNon-substrate0.6789
CYP450 1A2 substrateInhibitor0.8047
CYP450 2C9 inhibitorNon-inhibitor0.6942
CYP450 2D6 inhibitorNon-inhibitor0.6462
CYP450 2C19 inhibitorNon-inhibitor0.5788
CYP450 3A4 inhibitorNon-inhibitor0.8084
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5402
Ames testAMES toxic0.525
CarcinogenicityNon-carcinogens0.6336
BiodegradationNot ready biodegradable0.9701
Rat acute toxicity2.6454 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9901
hERG inhibition (predictor II)Non-inhibitor0.8204
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0fr2-0609000000-d672aaee80e39e3fd33f
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-01ba-0889000000-838856045f05e83d257f
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-0609000000-3a1affe986fdfaa27836
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-066s-1964000000-baf1491d50bd4ac57376
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0kai-0910000000-dac54cfc612aa58abd75
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-002f-2961000000-06b1ded3418f70de6cae
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-184.25742
predicted
DeepCCS 1.0 (2019)
[M+H]+186.74547
predicted
DeepCCS 1.0 (2019)
[M+Na]+194.88777
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Urokinase-type plasminogen activator
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Serine-type endopeptidase activity
Specific Function
Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.
Gene Name
PLAU
Uniprot ID
P00749
Uniprot Name
Urokinase-type plasminogen activator
Molecular Weight
48507.09 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]

Drug created at June 13, 2005 13:24 / Updated at July 02, 2020 13:16